Spruce Biosciences, Inc. SPRB
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -46.75%
- 1 year
- -56.75%
- Open
- 46.11
- Prev close
- 46.82
- Mkt cap
- 133.33M
- Vol
- 65.96K
- Avg vol
- 81.10K
- EPS
- -39.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 44.69
- High
- 46.62
- Forward P/E
- -0.41
- Beta
- 0.00
- Short ratio
- 0.10
- Inst. own
- 46.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.50446
- 200-d avg
- 0.668845
- 1y target
- 1.83
News
2 weeks ago businesswire.com
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
3 weeks ago businesswire.com
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
-
1 month ago benzinga.com
Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target
Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.
-
1 month ago benzinga.com
Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149
Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.
1 month ago businesswire.com
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
2 months ago gurufocus.com
Spruce Biosciences Announces Launch of MPS3BStudy.com
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disor
-
2 months ago benzinga.com
Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
Website Enables Families and Caregivers of Children with MPS IIIB to Learn About and Register Interest in the TA-ERT Expanded Access Program (EAP) and TrAnsform Confirmatory StudyTA-ERT EAP and…
2 months ago businesswire.com
Spruce Biosciences Announces Launch of MPS3BStudy.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
2 months ago businesswire.com
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104
Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.
-
2 months ago benzinga.com
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(6.68) per share which missed the analyst consensus estimate of $(5.80) by 15.17 percent. This is a 90.86…
2 months ago gurufocus.com
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord
2 months ago businesswire.com
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
2 months ago businesswire.com
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological…
3 months ago businesswire.com
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and…
3 months ago businesswire.com
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and…
-
3 months ago benzinga.com
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160
B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.
3 months ago businesswire.com
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
3 months ago seekingalpha.com
Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable…
-
4 months ago benzinga.com
Spruce Biosciences Joins Russell 3000 Index, Effective June 29
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical…
4 months ago gurufocus.com
Spruce Biosciences Joins the Russell 3000® Index
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological diso
4 months ago businesswire.com
Spruce Biosciences Joins the Russell 3000® Index
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
4 months ago businesswire.com
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
-
4 months ago benzinga.com
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.
4 months ago businesswire.com
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
-
4 months ago benzinga.com
Jones Trading Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $135
Jones Trading analyst Catherine Novack initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $135.
-
4 months ago benzinga.com
Spruce Biosciences Presents Data Demonstrating Long-Term Benefit Of Tralesinidase Alfa Enzyme Replacement Therapy In Patients With Sanfilippo Syndrome Type B At 18th International MPS Symposium
Data Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB, a Fatal Condition With No Approved TherapiesTreatment With Weekly TA-ERT Demonstrated Rapid and Durable…
4 months ago businesswire.com
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $200 to $150.
5 months ago businesswire.com
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
5 months ago businesswire.com
Spruce Biosciences to Participate in Upcoming Conferences in June
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for…
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.
-
5 months ago benzinga.com
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) Estimate
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(8.94) per share which missed the analyst consensus estimate of $(8.78) by 1.82 percent. This is a 62.75…
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus (UPDATED)
(Editor’s note: The futures and ETFs data were updated.) U.S. stock futures rose on Tuesday following Monday's decline. Futures of major benchmark indices edged up, with negotiating teams from the…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 months ago benzinga.com
Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with Anthropic to spend $100B on AWS.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 months ago benzinga.com
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session